APA (7th ed.) Citation

CL, H., AD, M., S, M., J, E., RL, G., B, R., & ML, A. (2006). Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors. Human gene therapy, 17(4), 440. https://doi.org/10.1089/hum.2006.17.440

Chicago Style (17th ed.) Citation

CL, Halbert, Miller AD, McNamara S, Emerson J, Gibson RL, Ramsey B, and Aitken ML. "Prevalence of Neutralizing Antibodies Against Adeno-associated Virus (AAV) Types 2, 5, and 6 in Cystic Fibrosis and Normal Populations: Implications for Gene Therapy Using AAV Vectors." Human Gene Therapy 17, no. 4 (2006): 440. https://doi.org/10.1089/hum.2006.17.440.

MLA (9th ed.) Citation

CL, Halbert, et al. "Prevalence of Neutralizing Antibodies Against Adeno-associated Virus (AAV) Types 2, 5, and 6 in Cystic Fibrosis and Normal Populations: Implications for Gene Therapy Using AAV Vectors." Human Gene Therapy, vol. 17, no. 4, 2006, p. 440, https://doi.org/10.1089/hum.2006.17.440.